ionis pharmaceuticals

News

FDA, Ionis and hereditary angioedema

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Yahoo · 16h

FDA approves Ionis’ hereditary angioedema drug

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

TipRanks on MSN · 15h

Ionis Pharmaceuticals Gains FDA Approval for DAWNZERA

An announcement from Ionis Pharmaceuticals ( ($IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved

Stocktwits on MSN6h

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter. BofA Securities ...

Fierce Pharma14h

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

23h

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5 ...

Nasdaq9mon

Where Ionis Pharmaceuticals Stands With Analysts - Nasdaq

Ionis Pharmaceuticals (NASDAQ: IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of ...

Hosted on MSN16h